Patterns of methylation of the c-myc gene in human colorectal cancer progression. by Sharrard, R. M. et al.
Br. J. Cancer (1992), 65, 667 672 .1 Macmillan
Patterns of methylation of the c-myc gene in human colorectal cancer
progression
R.M. Sharrard', J.A. Royds1, S. Rogers2 & A.J. Shorthouse3
'Oncogene Research Group, Departments ofPathology and Experimental and Clinical Microbiology, University ofSheffield
Medical School, Beech Hill Road, Sheffield SJO 2RX; 2Department ofPathology, University ofSheffield Medical School, Beech
Hill Road, Sheffield SJO 2RX; 3Department ofSurgery, Royal Hallamshire Hospital, Glossop Road, Sheffield S1O 2JF, UK.
Summary Over-expression and abnormal intracellular location of the product of the oncogene c-myc in
colonic dysplasia and neoplasia may be related to alterations in epigenetic mechanisms controlling the
functioning of this gene. We have investigated the methylation patterns of the c-myc oncogene in human
colorectal tissue representing various stages of dysplasia and neoplasia, including metastasis to liver, omentum
and lymph node. Comparison of normal and neoplastic tissues from the same patient showed a decrease in
methylation in a specific CCGG site in the third exon of c-myc through the progression from normal via
dysplastic to neoplastic and metastatic tissue. Quantitative analysis revealed that in colonic adenocarcinomas
an average of 66.1% and in metastatic deposits 83.1% of the myc gene DNA was hypomethylated at this site,
as compared to a value of 9.2% in normal colonic mucosa. Adenomatous polyps showed an average value of
50.5% and hyperplastic polyps, 24.8%. The results suggest that partial hypomethylation of the c-myc gene
third exon is associated with cell proliferation, and that deregulation of proliferation may be linked to the high
levels of hypomethylation, presumably involving both copies of the gene in some cells, which occur at a
relatively early stage in neoplastic progression.
Methylation of cytosine residues of DNA, especially in CpG
dinucleotide sequences, is thought to be closely involved with
gene expression (Razin & Riggs, 1980; Bird, 1986). It has
been established for some time that both the extent and the
specific pattern of DNA metlylation may be altered in
human tumours (Feinberg & Vogelstein, 1983); treatment of
cultured T-lymphoma cells with the hypomethylating agent
5-azacytidine causes them to become invasive and metastatic
in vivo (Habets et al., 1990). Hypomethylation of the 5' end
of a gene tends to be associated with its expression; altered
methylation patterns of genes involved in regulation of the
cell cycle and proliferation may thus be directly related to the
mechanism of malignancy. Significantly, in vivo methylation
of oncogenes after experimental transfection into cells
reverses their tumorigenicity (Renzo et al., 1989), and many
reports have demonstrated aberrant patterns of methylation
of growth-related genes such as c-myc (Cheah et al., 1984;
Ohtsuki et al.,1991), N-myc, K-ras, Ha-ras (Barbieri et al.,
1989), c-abl (Weitzman et al., 1989), erb-Al (Lipsanen et
al., 1988), and epidermal growth factor receptor (Kaneko et
al., 1985) in a variety of experimental animal tumour systems
and surgically-obtained human tumour specimens.
We have investigated the methylation patterns of the c-myc
oncogene in surgical specimens of human colorectal tissue
representing various stages of dysplasia and neoplasia, in-
cluding (when available) samples of involved lymph nodes
and metastases. Colorectal cancer usually shows a well-
defined progression through different histopathological
stages, from dysplasia in adenomatous polyps to adenocar-
cinoma and metastasis, and both the expression of the c-myc
gene and the distribution of its protein product as demon-
strated by immunohistochemistry show a distinct series of
changes in parallel with this progression (Royds et al., 1990;
1991). The known complexity of transcriptional control of
c-myc suggests that the pattern of methylation along the
entire sequence, and not merely the 5' end, should be con-
sidered as of potential importance in regulating its expres-
sion. Cheah et al. (1984) showed that myc DNA is
hypomethylated in some tumour cell lines and suggested that
hypomethylation of a specific CCGG sequence in the c-myc
third exon might be associated with raised expression of the
gene in human tumours. Hypomethylation of this site has
subsequently been found in human bladder tumours (del
Senno et al., 1989), hepatocellular carcinomas (Nambu et al.,
1987), thyroid carcinomas (del Senno et al., 1987), lympho-
proliferative diseases (Deguchi et al., 1987), myeloma cell
lines (Ohtsuki et al., 1991), and the translocated c-myc gene
in plasmacytoma (Dunnick et al., 1985). In contrast, the
methylatable sites at the 5' end of the gene are usually
unmethylated, even in copies of the gene which are transcrip-
tionally silent (Mango et al., 1989).
In the study presented in this paper we demonstrate that
normal colonic epithelium maintains a low but detectable
level of hypomethylation of the third-exon CCGG sequence;
hyperplasia is associated with a moderate loss of methylation
at this site, while much greater levels of hypomethylation
occur in adenomas, carcinomas and metastases. Low or
moderate hypomethylation of the 3' end of the c-myc gene
may thus be associated with proliferating cells in normal and
hyperplastic tissue; however, the quantitative difference in
hypomethylation between hyperplastic and adenomatous
(dysplastic) polyps suggests that high levels of demethylation
of the third exon, perhaps involving both copies within each
cell, may reflect or contribute to deregulation of proliferation
at an early stage in tumorigenesis.
Materials and methods
Tissue samples
Samples of colorectal polyps, tumours, metastatic deposits
and normal mucosa were obtained after surgical resection
and placed immediately in liquid nitrogen for storage until
used. Adjacent tissue was taken at the same time and pro-
cessed for routine histology and immunohistochemistry.
A total of 30 cases (17 male, 13 female) were studied, with
an age range of41 to 87 years. Polyps were obtained from 17
cases (ten male, seven female; age range 41 to 87 years);
samples of normal, tumour and (where available) polyp and
metastatic tissue were obtained from 16 cases (nine male,
seven female; age range 41 to 80 years).
Analysis ofDNA methylation
Tissue samples were retrieved from liquid nitrogen storage
and sectioned by cryostat. Representative sections of each
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sample were stained with haematoxylin and eosin for histo-
logical examination. The remaining cryostat sections were
used for preparation of DNA.
DNA was prepared by grinding frozen tissue in liquid
nitrogen followed by proteinase K treatment, phenol/
chloroform extraction and ethanol precipitation. Digestions
were performed using the following restriction enzymes:
Msp 1; Hpa II; Eco RI followed by Msp 1; Eco RI followed
by Hpa II; Sst 1 plus Xho 1. The digests were carried out as
follows: 10 jig of DNA was digested according to the sup-
pliers' recommendation (Eco RI, Sst 1, Xho 1) or with an
excess of restriction enzyme (5 unitsjig-' DNA; Msp 1,
Hpa II) overnight at 37°C in a total volume of 100 jil. For
digestions with Eco RI followed by Msp 1 or Hpa II, the
Eco RI digests were precipitated with ethanol and redis-
solved in the correct buffer before digestion with the second
enzyme.
Completeness of digestion under these conditions was
determined by comparison of the results with increasing
amounts of restriction endonuclease (up to 12 unitsjig-'
DNA). In order to establish that the Msp 1 and Hpa II
enzymes were still active at the end of the incubation, 15jil
aliquots of each digestion mixture were removed and 0.5lag
of lambda DNA added to these; after an additional 1 h at
37°C, these samples were tested by agarose gel electro-
phoresis, blotting and probing with labelled lambda DNA.
After digestion the DNA fragments were separated on 1%
agarose gels containing 0.5 jLg ml-' ethidium bromide in
TAE buffer (40 mM tris acetate pH 7.2-1 mM EDTA) and
photographed under UV illumination. Gels were then
equilibrated in 0.4M NaOH and the DNA transferred to
positively-charged Nylon membranes (Boehringer Mann-
heim) or Hybond N + membranes (Amersham) by capillary
blotting in this solution. The membranes were neutralised in
2 x SSC, air dried, and baked for 30 min at 10°C. Pre-
hybridisation was in 5 x SSC-0.1% sodium N-lauryl
sarcosine-2% casein (Boehringer Mannheim)-100fig ml-'
denatured salmon sperm DNA for 1 h at 65°C. Hybridisation
was in S x SSC - 0.1% sodium N-lauryl sarcosine-1% casein-
100jig ml-' denatured salmon sperm DNA, to which was
added myc probe (labelled with digoxigenin according to the
Boehringer Mannheim protocol) to a final concentration of
5-10 ng ml-'. The hybridisation was carried out overnight at
65°C. The filters were washed to a stringency of 0.1 x SSC
for the myc 1 and myc 2 probes or to 0.5 x SSC for the myc
3 probe. Detection was according to the manufacturer's
instructions using an anti-digoxigenin/alkaline phosphatase
conjugate. Final detection was either by incubation with
5-bromo-4-chloro-3-indolyl phosphate plus nitroblue tetra-
zolium (Life Technologies) for colour staining of the blots, or
by incubation with Lumi-Phos substrate (Boehringer Mann-
heim) for detection as lumigraphs on preflashed Hyperfilm-
MP (Amersham).
The following myc probes were used: myc 1 was the insert
from pUCLYXhl6 (Rabbitts et al., 1984), comprising 2 kb of
sequence from the Xho I site near the 5' end of the first exon
to a point near the 3' end of the first intron, and was a
generous gift from Dr T. Rabbitts; myc 2 was the insert from
the Amersham myc probe, comprising 1.5 kb of sequence
from the Sst 1 site near the centre of the first intron to the
Sst 1 site at the 3' end of the second exon; myc 3 was a
1.4 kb Cla I/Eco RI fragment comprising the third exon and
some sequence 3' to this, and was obtained from Dr M.
Goyns.
Quantitation ofmethylation patterns
The relative amounts of different fragments of the myc gene
detected in this system were quantitated as follows: after
exposure and development, the lumigraphs were placed on a
light box and recorded via a Newvicon video camera
attached to a Seescan Image Analysis system. The Seescan
was used to quantitate the exposure of each band (den-
sity x area). In order to correct for background, measure-
ments were made for equal areas immediately above and
below each band within the vertical track, and the average of
these measurements was subtracted from the measurement of
the band.
Results
Analysis ofDNA methylation
The methylation of c-myc DNA was investigated using the
isoschizomeric restriction enzymes Msp 1 and Hpa II. Msp 1
cuts CCGG and CmeCGG but not mcCCGG, while Hpa II
cuts CCGG only if neither C is methylated. Both enzymes
were found to work most effectively on DNA which had
been pre-cut with another enzyme, presumably thus allowing
greater accessibility of CCGG sites; we thus used Eco RI
digestion followed by Msp 1 or Hpa II, which we found to
give more reproducible results than Msp 1 or Hpa II alone.
Figure 1 shows the distribution of the CCGG sites in the
human c-myc gene in relation to the three exons; the probes
used in this study are also shown. Methylation in the first
exon of the myc gene was studied by using the myc 1
fragment to probe DNA samples digested with Xho 1 and
Sst 1. Xho 1 cuts the sequence CTCGAG, but only if the
second C is unmethylated. In Sst 1-digested myc, the
fragments recognised by the myc 1 first-exon probe have sizes
5.5, 0.6 and 1.5 kb; if the Xho 1 site in the first exon is cut,
the 5.5 kb fragment is cleaved to a segment of 0.9 kb (which
is 3' to the Xho 1 site) and one of the 4.6 kb which does not
overlap with the myc 1 probe. In all samples studied, myc 1
detected a similar pattern of 5.5, 0.9, 0.6 and 1.5 kb bands,
indicating a constant partial hypomethylation of approx-
imately half of these sites in all the tissues investigated. This
is of interest in view of the position of the Xho 1 site,
situated between the two major promoters P1 and P2, in the
c-myc gene; further studies are required to determine whether
such a pattern derives from one transcriptionally active and
one inactive copy of the gene.
In all tissues studied, digestion with either Msp 1 or Hpa II
caused fragmentation of the 5' end of the myc gene, reflecting
the high density of unmethylated CCGG sites within the first
exon. The number and small size of the fragments generated
makes impossible the individual analysis of the methylation
state of these sites. However, there is only one CCGG
sequence between the 3' end of the second exon and the
Eco RI site distal to the third exon. Digestion of human
colonic DNA with Eco Rl/Hpa II followed by probing with
the myc 3 sequence detected bands at 3.3 kb, 2.2kb and
1.1 kb. The relative amounts ofthe 3.3 kb and the 2.2 kb and
1.1 kb bands varied considerably between different samples;
however, no larger fragments were found. Eco R1/Msp 1
digests from all tissues contained only the 2.2 kb and 1.1 kb
bands. These results indicate that at least one of the group of
CCGG sequences at the 3' end of the second exon is always
unmethylated, and that the single CCGG site in the third
exon is variably methylated at the second C residue. The
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Figure 1 Organisation of the c-myc gene. The boxes represent
the three exons of the c-myc gene (the hatched areas showing the
translated sequences). The short vertical bars above the gene
indicate CCGG sequences (Msp 1/Hpa II sites); the vertical bars
below the gene indicate other restriction sites (S = Sst 1,
X = Xho 1, E = Eco R1). The lengths of relevant restriction
fragments is indicated above the gene. The extent of the
sequences corresponding to the probes used in this study (myc 1,
myc 2 and myc 3) are shown below the gene.C-myc METHYLATION IN COLORECTAL CANCER 669
results were confirmed using the myc 2 probe, which detects
the 3.3 kb and 2.2 kb fragments as well as smaller fragments
of about 0.4 and 0.2 kb generated by cutting at CCGG sites
within the first intron.
An initial study was carried out on 18 samples of normal
colorectal mucosa, 14 moderately differentiated adenocar-
cinomas of colon or rectum (of which six were classified as
Dukes B, seven as Dukes C, and one was recurrent), and six
metastases from colorectal tumours (two each from liver,
omentum and lymph nodes). Very low levels of hypomethyla-
tionof the third-exon CCGG site were found in normal
mucosa; significantly higher levels of hypomethylation (as
judged by eye from colour-stained Southern blots) were
observed in all tumours and metastases except for one of the
liver samples, which appeared to have a methylation level
similar to that in normal colonic epithelium and in the
surrounding liver tissue. In normal liver myc is highly
methylated (Kaneko et al., 1985); it is thus possible that in
some cases the surrounding tissue may exert a local effect on
the metastases.
Twenty-nine tissue samples which had been identified and
excised as polyps during surgery were also examined in this
part of the study. Histological examination classified these as
follows: eight hyperplastic polyps, six tubular adenomas,
eight tubulovillous adenomas, and four villous adenomas; the
remaining three samples showed no evidence of hyperplasia
or dysplasia, although two showed inflammatory infiltration.
Analysis of the third-exon CCGG site in these samples
revealed higher levels of hypomethylation as compared with
normal colonic mucosa in all the hyperplastic polyps and
adenomas, but not in the three samples which lacked hyper-
plastic or dysplastic changes.
Quantitation ofhypomethylation ofthe third-exon CCGG site
The above observations suggested that the degree of
hypomethylation of the CCGG site in the third exon was
increased in dysplastic and neoplastic colonic tissue. Quan-
titative analysis of the degree of hypomethylation of this site
was carried out on selected specimens as follows: ten samples
of normal colorectal mucosa; nine moderately differentiated
adenocarcinomas (four of Dukes stage B and five of Dukes
stage C); four metastases (two from omentum, two from
lymph nodes); five hyperplastic polyps; ten adenomas (four
tubular, three tubulovillous, three villous). Eco R1/Hpa II
digests of DNA from these tissues were probed with the myc
3 sequence (Figure 2) and the degree of hypomethylation
quantitated by Seescan analysis (see Materials and methods).
The percentage hypomethylation was calculated according to
the formula
density of 2.2 kb band + density of 1.1 kb band x 100%
density of 3.3 kb + 2.2 kb + 1.1 kb bands
The results are shown in Table I. Normal colonic mucosa
showed an average hypomethylation level of 9.2% (range 4.5
to 16.3, n = 10), while the tumours gave an average of 66.1%
(range 24.1 to 82.6, n = 9); tumours of Dukes stage B were
slightly lower (average 62.7%, n = 4) than those of stage C
(average 68.9%, n = 5). The highest hypomethylation values
occurred in the metastatic tissues (72.7 and 83.5% in lymph
nodes, 88.0 and 88.2% in omentum; overall average 83.1%).
The results obtained from polyp samples confirmed that
these tissues contained hypomethylated third-exon CCGG
sites. All but one of the hyperplastic polyps had hypo-
methylation values greater than the normal range; the
average value was 24.8% (range 10.3 to 39.7, n = 5).
Adenomas had hypomethylation values intermediate between
hyperplastic polyps and tumours: the overall average was
50.5% (range 23.0 to 69.0, n = 10). It may be noted that two
of the three adenomas with values less than 45% came from
a single subject (patient no. 11).
The degree of hypomethylation reported in Table I
represents the average of all the myc DNA in the sample.
Histological examination of the representative cryostat sec-
tions revealed that in a few cases the specimen contained
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Figure 2 Southern blots of human colorectal DNA probed with
c-myc. DNA from human colorectal tissues was isolated, digested
with Eco RI and Hpa II, and separated on agarose gels.
Southern blots of the gels were probed with digoxigenin-labelled
myc 3 probe and detected by antidigoxigenin/alkaline phos-
phatase complex and chemiluminescence as described in Mater-
ials and methods. The sizes of the DNA fragments in the bands
are indicated in kb. a, Tissue samples: 1, Patient 2, normal
mucosa; 2, Patient 2, moderately differentiated adenocarcinoma,
Dukes B; 3, Patient 9, normal mucosa; 4, Patient 9, moderately
differentiated adenocarcinoma, Dukes C; 5, Patient 3, normal
mucosa; 6, Patient 3, tubular adenoma with mild dysplasia; 7,
Patient 3, moderately differentiated adenocarcinoma, Dukes B.
b, Tissue samples: 1, Patient 12, tubulovillous adenoma with mild
dysplasia, 10mm; 2, Patient 13, hyperplastic polyp, 3 mm; 3,
Patient 14, tubulovillous adenoma with moderate dysplasia,
30mm; 4, Patient 16, hyperplastic polyp, 3 mm; 5, Patient 16,
tubular adenoma with mild dysplasia, 15 mm; 6, Patient 17,
tubular adenoma with mild dysplasia, 20mm.
areas of normal mucosa, stroma, or muscle; furthermore,
examination of the cryostat sections and of sections of
paraffin-embedded material from adjoining samples showed
that the areas of hyperplasia, dysplasia and neoplasia con-
tained a proportion of interstitial stromal and infiltrating
inflammatory cells. The proportion of abnormal epithelial670 R.M. SHARRARD et al.
cells (hyper-, dys- or neoplastic) out of the total cellular
composition of the material used for DNA extraction was
estimated from these sections (Table I). The proportion of
abnormal epithelial cells in the composition of the samples of
hyperplastic and adenomatous polyps is relatively constant,
indicating that increased hypomethylation levels in adeno-
matous polyps accurately reflect the greater neoplastic poten-
tial of these tissues. However, the quantitative contribution
made to the overall level of myc hypomethylation by
infiltrating inflammatory cells and surrounding normal
epithelium and stroma cannot be determined exactly in this
study; local 'field effects' from growth factors secreted by
Table I Hypomethylation ofthe third-exon CCGG site in normal, dysplastic and neoplastic colon
tissue assessed by myc 3 probing of Eco R1/Hpa II digests
Patient Hypomethylation Estimated % abnormal
no. Histology % epithelial cellsa
1 Normal mucosa 12.4
Moderately differentiated 79.2 45
adenocarcinoma, Dukes B
2 Normal mucos
Moderately differentiated
adenocarcinoma, Dukes B
3 Normal mucosa
Hyperplastic polyp, 5 mm
Tubular adenoma, mild
dysplasia, 12mm
Moderately differentiated
adenocarcinoma, Dukes B
4 Normal mucosa
Moderately differentiated
adenocarcinoma, Dukes C
Lymph node with metastasis
5 Normal mucosa
Moderately differentiated
adenocarcinoma, Dukes B
6 Normal mucosa
Moderately differentiated
adenocarcinoma, Dukes C
7 Normal mucosa
Moderately differentiated
adenocarcinoma, Dukes C
Omental metastasis 1
Omental metastasis 2
8 Normal mucosa
Moderately differentiated
adenocarcinoma, Dukes C
Lymph node with metastasis
9 Normal mucosa
Hyperplastic polyp, 4 mm
Moderately differentiated
adenocarcinoma, Dukes C
10 Normal mucosa
Hyperplastic polyp, 5 mm
Tubulovillous adenoma, 30 mm
Villous adenoma, 70 mm
11 Villous adenoma with moderate
dysplasia, 15 mm
Villous adenoma with severe
dysplasia and carcinoma
arising, 10mm
12 Tubulovillous adenoma with mild
dysplasia, 10mm
13
14
Hyperplastic polyp, 3 mm
Tubulovillous adenoma with
moderate dysplasia, 30 mm
15 Tubular adenoma with mild
dysplasia, 2 mm
16 Hyperplastic polyp, 3 mm
Tubular adenoma with mild
dysplasia, 15 mm
17 Tubular adenoma with mild
dysplasia, 20 mm
4.5
77.8
7.7
39.7
47.3
69.6
7.8
75.7
72.7
4.5
24.1
16.3
46.8
7.0
63.3
88.0
88.2
8.4
82.6
83.5
7.3
17.4
76.1
15.7
10.3
27.0
55.2
23.0
29.7
63.4
17.0
65.6
69.0
39.4
62.1
62.2
35
90
60
65
45
45
largely necrotic
tissue
<50
65
75
75
70
70
N/A
70
70
60
60
70
80
80
N/A
70
70
70
70
'These results were obtained from examination ofcryostat sections of the tissues analysed and
sections of paraffin-embedded blocks of adjacent tissue. 'Abnormal' here includes hyperplastic,
dysplastic and neoplastic cells. N/A = result not available.C-myc METHYLATION IN COLORECTAL CANCER 671
proliferating epithelial cells might induce demethylation of
myc in lymphocytes and other cells in which the DNA is
usually heavily methylated. Nevertheless, calculations show
that whatever level of hypomethylation is present in the
inflammatory cells and surrounding normal tissue, the
epithelial cells of hyperplastic polyps cannot show
hypomethylation levels as high as 50%, whereas in at least
some of the adenomatous polyps the cells must exceed this
value.
The very high values for myc hypomethylation in
adenocarcinomas and their metastases when adjusted for the
presence of infiltrating non-neoplastic cells suggest that the
myc DNA in the tumour cells may be completely un-
methylated. In some cases, hypomethylation in the tumour
cell population (after subtraction of the 'normal' cell compo-
nent) appears to exceed 100%. Such values could arise if the
dominant tumour cell population in a sample was hyper-
diploid and fully hypomethylated. The possibility also exists
here that neoplastic cells may influence the DNA methylation
state of the surrounding stromal and lymphoid cells; this
question might be resolved by analysis of DNA methylation
in sorted cell populations derived from disaggregated fresh
tumour specimens.
Discussion
At least eight mutational events may be involved in the
progression to colonic adenocarcinoma (Solomon, 1990), in-
cluding allele losses from chromosomes 1, 5, 6, 8, 9, 17, 18
and 22 (Vogelstein et al., 1989). Goelz et al. (1985), however,
indicated that some of the earliest events in colonic dysplasia
are epigenetic: both the extent and the pattern of DNA
methylation were altered in adenomatous polyps. In this
study we show hypomethylation of a specific site in the third
exon of c-myc in the earliest stages ofpolyp formation which
increases with tumour progression.
In normal colonic mucosa, immunohistochemistry shows
c-myc protein to be restricted to the nuclei of cells in the
proliferating zones of the crypts; these cells may account for
the limited extent of myc gene third-exon hypomethylation
found in this tissue. In contrast, the cells of adenomatous
polyps contain high levels of cytoplasmic myc protein which
is associated with the polyribosomes as well as nuclear myc
protein in the dense chromatin, while tumour cells show
pan-cellular staining (Royds et al., 1990; 1991). This progres-
sive deregulation of myc expression through dysplasia to
neoplasia is paralleled by increasing loss of third-exon
methylation. Notably, the highly proliferative, but not dys-
plastic, cells of hyperplastic polyps show hypomethylation
levels intermediate between normal and dysplastic tissue. As
most of the adenoma and carcinoma samples showed levels
of hypomethylation over 50%, at least some of the dysplastic
cells in these tissues must have lost the methylation of both
alleles. Hypomethylation of the second allele of c-myc may
thus be significant in the deregulation of proliferation
associated with colonic tumorigenesis. However, some colo-
rectal tumours must arise via combinations of genetic events
which do not involve myc deregulation, as in Patient 11, who
yielded two specimens of villous adenoma with relatively low
levels of hypomethylation of the myc third exon detectable in
both.
Hypomethylation of proliferation control genes in dys-
plasia may result from continous expression in response to
long-term exposure to mitogenic stimuli. Alternatively,
exposure to oxidants generated by activated phagocytes in
chronic inflammation may induce gene-specific alterations in
DNA methylation (Weitzman et al., 1989). It will thus be of
interest to investigate possible correlations between altered
methylation patterns and accumulation of lymphoid cells in
very early adenomas.
Myc protein has been implicated both in progression
through the cell cycle and in differentiation-related regulation
of transcription. Over-expressed myc protein in dysplastic
and tumour cells, accumulating in the cytoplasm and trans-
ferring continuously to the nucleus, may alter cellular
response to growth factors and abrogate normal growth
control mechanisms by preventing cells from escaping from
the proliferation cycle (Freytag, 1988). C-myc protein may
also control its own expression by binding, directly or
indirectly, to the c-myc gene; if this interaction is affected by
DNA methylation (see Prendergast & Ziff, 1991), there may
be a feedback effect between hypomethylation of the third
exon of myc and deregulation of expression. Recent studies
in our laboratory have shown that a 34-base pair sequence
spanning the CCGG site of the c-myc third exon exhibits
methylation-dependent binding of specific protein species
from normal colonic epithelium; dysplastic tissue yields an
altered binding pattern (Sharrard et al., 1991 and in prepara-
tion). Alterations in the downstream methylation pattern
may thus affect myc expression through binding of trans-
acting factors, either directly or via induction of longer-range
conformational changes.
Finally, as the effects investigated in this study relate to
very early events in colonic tumorigenesis, we suggest that
hypomethylation of the CCGG site of the third exon of myc
may provide an indicator of malignant progression of dys-
plastic tissue in the colon and may thus be of diagnostic and
prognostic value in colorectal cancer patients.
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